TyrNovo, Kitov deal

Kitov acquired 56% of TyrNovo for $2 million in cash and $1.8 million in stock. TyrNovo’s NT219, a small molecule inhibitor of insulin receptor substrate 1 (IRS1), IRS2 and signal transducer and activ...